Leerink Partnrs Has Bullish Outlook for SRPT FY2024 Earnings
Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...
RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...